

CITATION REPORT

List of articles citing

Clinicians should stop prescribing sildenafil for fetal growth restriction (FGR): comment from the STRIDER Conso

DOI: 10.1002/uog.19186

Ultrasound in Obstetrics and Gynecology, 2018, 52, 295-296.

Source: <https://exaly.com/paper-pdf/71299650/citation-report.pdf>

Version: 2024-04-10

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
64	Sildenafil crosses the placenta at therapeutic levels in a dually perfused human cotyledon model. <i>American Journal of Obstetrics and Gynecology</i> , 2018 , 219, 619.e1-619.e10	6.4	17
63	Viagra for fetal growth restriction: STRIDER Consortium replies to letter by Symonds and Budge. <i>BMJ, The</i> , 2018 , 363, k4872	5.9	2
62	Antenatal sildenafil treatment improves neonatal pulmonary hemodynamics and gas exchange in lambs with diaphragmatic hernia. <i>Ultrasound in Obstetrics and Gynecology</i> , 2019 , 54, 506-516	5.8	9
61	Gasotransmitters in health and disease: a mitochondria-centered view. <i>Current Opinion in Pharmacology</i> , 2019 , 45, 87-93	5.1	9
60	Pre-eclampsia: pathophysiology and clinical implications. <i>BMJ, The</i> , 2019 , 366, l2381	5.9	275
59	Therapeutic interventions: The importance of including diseased and healthy samples in preclinical studies. <i>EBioMedicine</i> , 2019 , 45, 5-6	8.8	
58	Safety Evaluation of Tadalafil Treatment for Fetuses with Early-Onset Growth Restriction (TADAFER): Results from the Phase II Trial. <i>Journal of Clinical Medicine</i> , 2019 , 8,	5.1	8
57	Maternal and Fetal Therapy: Can We Optimize Fetal Growth?. 2019 , 287-301		
56	Subcutaneous maternal resveratrol treatment increases uterine artery blood flow in the pregnant ewe and increases fetal but not cardiac growth. <i>Journal of Physiology</i> , 2019 , 597, 5063-5077	3.9	13
55	Current and emerging pharmacotherapy for emergency management of preeclampsia. <i>Expert Opinion on Pharmacotherapy</i> , 2019 , 20, 701-712	4	10
54	Mortality in the UK STRIDER trial of sildenafil therapy for the treatment of severe early-onset fetal growth restriction. <i>The Lancet Child and Adolescent Health</i> , 2019 , 3, e2-e3	14.5	11
53	Placental effects and transfer of sildenafil in healthy and preeclamptic conditions. <i>EBioMedicine</i> , 2019 , 45, 447-455	8.8	21
52	Protect-me: a parallel-group, triple blinded, placebo-controlled randomised clinical trial protocol assessing antenatal maternal melatonin supplementation for fetal neuroprotection in early-onset fetal growth restriction. <i>BMJ Open</i> , 2019 , 9, e028243	3	16
51	Prenatal Sildenafil Therapy Improves Cardiovascular Function in Fetal Growth Restricted Offspring of Dahl Salt-Sensitive Rats. <i>Hypertension</i> , 2019 , 73, 1120-1127	8.5	6
50	Perinatal deaths after sildenafil treatment of fetal growth restriction raise the issue of safety in randomised clinical trials. <i>Pharmacoepidemiology and Drug Safety</i> , 2019 , 28, 437-438	2.6	3
49	Antenatal therapy with sildenafil: don't throw the baby out with the bathwater. <i>Ultrasound in Obstetrics and Gynecology</i> , 2019 , 53, 274-275	5.8	5
48	STRIDER NZAus: a multicentre randomised controlled trial of sildenafil therapy in early-onset fetal growth restriction. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2019 , 126, 997-1006	3.7	25

47	Reply. <i>Ultrasound in Obstetrics and Gynecology</i> , 2019 , 53, 275	5.8	
46	Neonatal Cardiovascular Function after Antenatal Sildenafil for Severe, Early-Onset Intrauterine Growth Restriction: A Substudy of the STRIDER-NZAus Randomized Placebo-Controlled Trial. <i>Journal of Pediatrics: X</i> , 2019 , 1, 100009	0.9	0
45	Prenatal diagnosis and management of congenital diaphragmatic hernia. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2019 , 58, 93-106	4.6	16
44	Established and emerging therapeutic uses of PDE type 5 inhibitors in cardiovascular disease. <i>British Journal of Pharmacology</i> , 2020 , 177, 5467-5488	8.6	34
43	Maternal low molecular weight heparin versus sildenafil citrate for fetal growth restriction: a randomized, parallel groups, open-label clinical trial. <i>Journal of Perinatology</i> , 2020 , 40, 715-723	3.1	1
42	Effects of nifedipine and sildenafil on placental hemodynamics and gas exchange during fetal hypoxemia in a chronic sheep model. <i>Placenta</i> , 2020 , 90, 103-108	3.4	2
41	Antenatal sildenafil citrate treatment increases offspring blood pressure in the placental-specific knockout mouse model of FGR. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2020 , 318, H252-H263	5.2	7
40	Novel approaches to combat preeclampsia: from new drugs to innovative delivery. <i>Placenta</i> , 2020 , 102, 10-16	3.4	10
39	AMP-activated protein kinase activator AICAR attenuates hypoxia-induced murine fetal growth restriction in part by improving uterine artery blood flow. <i>Journal of Physiology</i> , 2020 , 598, 4093-4105	3.9	11
38	Hydroxychloroquine as a Preventive and Therapeutic Option in Preeclampsia - a Literature Review. <i>Geburtshilfe Und Frauenheilkunde</i> , 2020 , 80, 679-685	2	7
37	Maternal sildenafil impairs the cardiovascular adaptations to chronic hypoxaemia in fetal sheep. <i>Journal of Physiology</i> , 2020 , 598, 4405-4419	3.9	6
36	ISUOG Practice Guidelines: diagnosis and management of small-for-gestational-age fetus and fetal growth restriction. <i>Ultrasound in Obstetrics and Gynecology</i> , 2020 , 56, 298-312	5.8	114
35	Developmental Evaluation of Infants Who Have Received Tadalafil in Utero for Fetal Growth Restriction. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	0
34	Antenatal approaches in the therapy of BPD. 2020 , 169-191		
33	Safety and efficacy of sildenafil citrate to reduce operative birth for intrapartum fetal compromise at term: a phase 2 randomized controlled trial. <i>American Journal of Obstetrics and Gynecology</i> , 2020 , 222, 401-414	6.4	14
32	Placenta-targeted treatment strategies: An opportunity to impact fetal development and improve offspring health later in life. <i>Pharmacological Research</i> , 2020 , 157, 104836	10.2	17
31	Preeclampsia beyond pregnancy: long-term consequences for mother and child. <i>American Journal of Physiology - Renal Physiology</i> , 2020 , 318, F1315-F1326	4.3	36
30	Vitamin D improves pulmonary function in a rat model for congenital diaphragmatic hernia. <i>Archives of Biochemistry and Biophysics</i> , 2021 , 700, 108769	4.1	1

29	Transplacental Transfer and Fetal Pharmacodynamics of Sildenafil in the Pregnant Sheep Model. <i>Fetal Diagnosis and Therapy</i> , 2021 , 48, 411-420	2.4	0
28	Use of sildenafil and other phosphodiesterase type 5 inhibitors among pregnant women in Scandinavia. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2021 , 100, 2111-2118	3.8	0
27	Pharmacokinetics and pharmacodynamics of sildenafil in fetal lambs on extracorporeal support. <i>Biomedicine and Pharmacotherapy</i> , 2021 , 143, 112161	7.5	1
26	Complementary Effect of Maternal Sildenafil and Fetal Tracheal Occlusion Improves Lung Development in the Rabbit Model of Congenital Diaphragmatic Hernia. <i>Annals of Surgery</i> , 2020 , 275,	7.8	3
25	Arterial Stiffness as a Cardiovascular Risk Factor for the Development of Preeclampsia and Pharmacopreventive Options. <i>Current Vascular Pharmacology</i> , 2021 ,	3.3	
24	Effect of antenatal tetramethylpyrazine on lung development and YAP expression in a rat model of experimental congenital diaphragmatic hernia.		
23	A pilot study on investigating the role of Salvia miltiorrhiza in fetal growth restriction. <i>Bioscience Reports</i> , 2020 , 40,	4.1	0
22	Effect of antenatal tetramethylpyrazine on lung development and YAP expression in rat model of experimental congenital diaphragmatic hernia. <i>International Journal of Clinical and Experimental Pathology</i> , 2020 , 13, 81-88	1.4	
21	A review of ex vivo placental perfusion models: an underutilized but promising method to study maternal-fetal interactions. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2021 , 1-13	2	1
20	Short-term outcomes of phosphodiesterase type 5 inhibitors for fetal growth restriction: a study protocol for a systematic review with individual participant data meta-analysis, aggregate meta-analysis, and trial sequential analysis. <i>Systematic Reviews</i> , 2021 , 10, 305	3	0
19	Antenatal Management of Congenital Diaphragmatic Hernia: what's next ?. <i>Prenatal Diagnosis</i> , 2022 ,	3.2	0
18	Fetal lung regeneration using stem cell-derived extracellular vesicles: A new frontier for pulmonary hypoplasia secondary to congenital diaphragmatic hernia.. <i>Prenatal Diagnosis</i> , 2022 ,	3.2	0
17	Phosphodiesterase-5 inhibitors in Pregnancy: Systematic review and meta-analysis of maternal and perinatal safety and clinical outcomes.. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2022 ,	3.7	0
16	Placental transfer and vascular effects of pharmaceutical drugs in the human placenta ex vivo: A review.. <i>Placenta</i> , 2022 , 122, 29-45	3.4	0
15	Neonatal and fetal therapy of congenital diaphragmatic hernia-related pulmonary hypertension.. <i>Archives of Disease in Childhood: Fetal and Neonatal Edition</i> , 2021 ,	4.7	0
14	Assessment of the value of measuring soluble fms-like tyrosine kinase-1 and placental growth factor levels following administration of tadalafil to treat fetal growth restriction.. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2021 , 1-5	2	
13	Challenges and Pitfalls: Performing Clinical Trials in Patients With Congenital Diaphragmatic Hernia.. <i>Frontiers in Pediatrics</i> , 2022 , 10, 852843	3.4	
12	Tadalafil treatment for fetuses with early-onset growth restriction: a protocol for a multicentre, randomised, placebo-controlled, double-blind phase II trial (TADAFER IIb). <i>BMJ Open</i> , 2022 , 12, e054925 ³		

11	Halting the Canadian STRIDER randomised controlled trial of sildenafil for severe, early-onset fetal growth restriction: ethical, methodological, and pragmatic considerations. <i>BMC Research Notes</i> , 2022 , 15,	2.3	○
10	Prenatal treprostinil reduces the pulmonary hypertension phenotype in the rat model of congenital diaphragmatic hernia. <i>EBioMedicine</i> , 2022 , 81, 104106	8.8	
9	A Summary of Chinese Expert Consensus on Fetal Growth Restriction (An Update on the 2019 Version). <i>Maternal-Fetal Medicine</i> , 2022 , 4, 162-168	0.6	○
8	Watermelon-Derived Extracellular Vesicles Influence Human Ex Vivo Placental Cell Behavior by Altering Intestinal Secretions. 2200013		1
7	Sildenafil during the 2nd and 3rd Trimester of Pregnancy: Trials and Tribulations. 2022 , 19, 11207		1
6	Repurposing existing drugs as a therapeutic approach for the prevention of preterm birth. 2022 ,		○
5	British Society for Rheumatology guideline on prescribing drugs in pregnancy and breastfeeding: comorbidity medications used in rheumatology practice.		○
4	Executive Summary: British Society for Rheumatology guideline on prescribing drugs in pregnancy and breastfeeding: comorbidity medications used in rheumatology practice.		○
3	Analysis of a maternal health medicines pipeline database 2000-2021: New candidates for the prevention and treatment of fetal growth restriction. 2023 , 130, 653-663		○
2	Safety and Efficacy of phosphodiesterase-5 (PDE-5) inhibitors in fetal growth restriction: a systematic literature review and meta-analysis.		○
1	PBPK-based dose finding for sildenafil in pregnant women for antenatal treatment of congenital diaphragmatic hernia. 14,		○